SLC7A5

Across TCGA pan-cancer cohorts, SLC7A5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC7A5 data layer compared with 26 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SLC7A5 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SLC7A5 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where SLC7A5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.701	0.941	<.001	86	view →
PDAC	OS	Median	III,IV	0.229	0.733	.001	52	view →
HNSC	DFS	Median	III,IV	0.895	0.265	.001	49	view →
LUAD	DFS	Median	II,III,IV	0.984	0.690	.008	15	view →
GBM	OS	Tertile	All	0.892	0.769	.010	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC7A5–CCRCC (OS)

Open the CCRCC breakdown →